Dogwood Therapeutics annual return on equity
2021
2022
2023
2025
Dogwood Therapeutics Return on Equity (ROE) Growth & History (DWTX)
Dogwood Therapeutics's return on equity was −105.78% for fiscal 2025.
View full Dogwood Therapeutics company overviewDogwood Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −105.78% | — |
| 2023 | 2023-12-31 | −95.14% | +17.09 pp |
| 2022 | 2022-12-31 | −112.22% | −40.40 pp |
| 2021 | 2021-12-31 | −71.83% | — |
Dogwood Therapeutics quarterly return on equity
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −15.48% | +39.05 pp |
| Q1 2026 | 2026-03-31 | −6.41% | — |
| Q4 2025 | 2025-12-31 | −9.20% | — |
| Q3 2025 | 2025-09-30 | −222.75% | −111.09 pp |
| Q2 2025 | 2025-06-30 | −54.53% | −18.26 pp |
| Q3 2024 | 2024-09-30 | −111.65% | −85.53 pp |
| Q2 2024 | 2024-06-30 | −36.26% | −9.24 pp |
| Q1 2024 | 2024-03-31 | −39.97% | −17.16 pp |
| Q4 2023 | 2023-12-31 | −25.75% | −1.04 pp |
| Q3 2023 | 2023-09-30 | −26.13% | +5.35 pp |
| Q2 2023 | 2023-06-30 | −27.03% | +14.15 pp |
| Q1 2023 | 2023-03-31 | −22.81% | +8.65 pp |
| Q4 2022 | 2022-12-31 | −24.71% | +2.32 pp |
| Q3 2022 | 2022-09-30 | −31.47% | −11.78 pp |
| Q2 2022 | 2022-06-30 | −41.17% | −24.03 pp |
| Q1 2022 | 2022-03-31 | −31.46% | −20.75 pp |
| Q4 2021 | 2021-12-31 | −27.03% | — |
| Q3 2021 | 2021-09-30 | −19.69% | — |
| Q2 2021 | 2021-06-30 | −17.14% | — |
| Q1 2021 | 2021-03-31 | −10.71% | — |
Dogwood Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Dogwood Therapeutics's return on equity decreased from −71.83% to −105.78%, a change of −33.95 percentage points. The latest reported quarter, Q2 2026, shows −15.48%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dogwood Therapeutics source filings ↗